Skip to main content

Transgenomic Receives Warning from Nasdaq for Failing to Maintain Minimum Share Bid Price

NEW YORK, Feb. 23 (GenomeWeb News) - Transgenomic has received a letter from the Nasdaq indicating that the company does not comply with the $1 minimum bid price requirement, the company announced today.

 

According to the letter, which was received Feb. 15, Transgenomic has until Aug. 14 to regain compliance. The share price must close at or above $1 for 10 consecutive days, though Nasdaq may require the company to maintain that closing price for a longer period before determining compliance.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.